Nexviazyme
Nexviazyme ingredients
| Active ingredient | Strength |
|---|---|
| Avalglucosidase Alfa | 100 mg/10mL |
What Nexviazyme is used for
The FDA lists the approved uses on the official label (below). In the EU, avalglucosidase alfa is approved as Nexviadyme for:
Nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with Pompe disease (acid alpha-glucosidase deficiency).
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Nexviazyme
- Generic name
- Avalglucosidase alfa-ngpt
- Made by
- Genzyme Corporation
- Forms
- Injection, Powder, Lyophilized, For Solution
- Given
- Intravenous
- Drug class
- Hydrolytic Lysosomal Glycogen-specific Enzyme
- FDA approval
- Biologic licence (BLA) BLA761194
- On the US market since
- 2021
Official information
- Nexviazyme prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Avalglucosidase alfa-ngpt)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Nexviazyme?
Nexviazyme (Avalglucosidase alfa-ngpt) is a specialist medicine made by Genzyme Corporation, approved by the US FDA.
What are the ingredients of Nexviazyme?
Nexviazyme contains Avalglucosidase Alfa (100 mg/10mL).
Is Nexviazyme approved in Europe?
The same active substance is approved in the EU as Nexviadyme.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA